Centene Corp (CNC)
Centene Corp (CNC) carries a ŷRobot AI score of 60 out of 100. The model's fair value estimate is $73.66, 3.4% above the last close of $71.27. The chart signal reads Sell.
| Metric | CNC |
|---|---|
| AI score | 60 / 100 |
| Chart signal | Sell |
| Fair value estimate | $73.66 |
| Upside to fair value | 3.4% |
| Previous close | $71.27 |
| P/E | 23.58 |
| Price / sales | 0.19 |
| Market cap | $34.89B |
| EPS | 2.91 |
| Revenue growth | 9.7% |
| 1-year price change | 3.3% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about CNC
Is CNC overvalued or undervalued right now?
As of Oct 30, 2026, ŷRobot's fair-value model estimates Centene Corp (CNC) at $73.66 against a last close of $71.27, implying 3.4% upside to the model's estimate.
Is CNC's chart signal bullish or bearish?
The chart-signal model classifies CNC as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is CNC's ŷRobot AI score?
CNC scores 60 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is CNC stock expensive on P/E and P/S?
CNC trades at 23.6 times earnings and 0.2 times sales as of Nov 13, 2026.
What does CNC's seasonal forecast show?
ŷRobot's seasonal forecast curve for CNC reads +0.8% at 30 days, +1.0% at 90 days, and +3.3% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is CNC growing?
Centene Corp's revenue growth is +9.7% and free-cash-flow growth is +33.8% on the latest reported figures.
CNC chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.